4.8 Article

Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program

期刊

CIRCULATION
卷 133, 期 13, 页码 1240-1248

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.115.020207

关键词

pulmonary hypertension; pulmonary heart disease; outcome assessment

资金

  1. National Institutes of Health (NIH) [1K08HL11207-01A1]
  2. American Heart Association [15GRNT25080016]
  3. Pulmonary Hypertension Association
  4. Cardiovascular Medical Research and Education Fund
  5. Klarman Foundation at Brigham and Women's Hospital
  6. Gilead Young Scholars Foundation (Gilead Sciences)
  7. Veterans Affairs Health Services Research and Development Career Development Award [CDA 08-021]
  8. Dunlevie Family Fund
  9. Office of Research and Development: Biomedical Laboratory Research and Development Service (MERIT Review Award) [1I01BX002042-01A2, IBX000711A]
  10. Department of Veterans Affairs, Veterans Health Administration
  11. Catherine and Lowe Berger and Pauline L. Ford Scholarship in Pulmonary Medicine
  12. Department of Medicine, Indiana University
  13. VA Merit Award from the Department of Veterans Affairs, Veterans Health Administration
  14. Office of Research and Development: Clinical Science Research and Development Service
  15. NIH/National Heart, Lung, and Blood Institute (NHLBI) [1U01HL125215-01]
  16. Junior Faculty Endowment by Vera Moulton Wall Center for Pulmonary Vascular Disease
  17. NIH/NHLBI/National Institute of Allergy and Infectious Diseases [PO1 HL108797, UO1 HL107393, R24 HL123767, N01 HV00242, ASCO1]
  18. Department of Medicine, Alpert Medical School

向作者/读者索取更多资源

Background- Pulmonary hypertension (PH) is associated with increased morbidity across the cardiopulmonary disease spectrum. Based primarily on expert consensus opinion, PH is defined by a mean pulmonary artery pressure (mPAP) >= 25 mm Hg. Although mPAP levels below this threshold are common among populations at risk for PH, the relevance of mPAP < 25 mm Hg to clinical outcome is unknown. Methods and Results- We analyzed retrospectively all US veterans undergoing right heart catheterization (2007-2012) in the Veterans Affairs healthcare system (n=21 727; 908-day median follow-up). Cox proportional hazards models were used to evaluate the association between mPAP and outcomes of all-cause mortality and hospitalization, adjusted for clinical covariates. When treating mPAP as a continuous variable, the mortality hazard increased beginning at 19 mm Hg (hazard ratio [HR]=1.183; 95% confidence interval [CI], 1.004-1.393) relative to 10 mm Hg. Therefore, patients were stratified into 3 groups: (1) referent (<= 18 mm Hg; n=4 207); (2) borderline PH (19-24 mm Hg; n=5 030); and (3) PH (>= 25 mm Hg; n=12 490). The adjusted mortality hazard was increased for borderline PH (HR=1.23; 95% CI, 1.12-1.36; P < 0.0001) and PH (HR=2.16; 95% CI, 1.96-2.38; P < 0.0001) compared with the referent group. The adjusted hazard for hospitalization was also increased in borderline PH (HR=1.07; 95% CI, 1.01-1.12; P=0.0149) and PH (HR=1.15; 95% CI, 1.09-1.22; P < 0.0001). The borderline PH cohort remained at increased risk for mortality after excluding the following high-risk subgroups: (1) patients with pulmonary artery wedge pressure > 15 mm Hg; (2) pulmonary vascular resistance >= 3.0 Wood units; or (3) inpatient status at the time of right heart catheterization. Conclusions- These data illustrate a continuum of risk according to mPAP level and that borderline PH is associated with increased mortality and hospitalization. Future investigations are needed to test the generalizability of our findings to other populations and study the effect of treatment on outcome in borderline PH.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据